Blood online
Home About Blood Authors Subscriptions Permission Advertising Public Access contact us
 

 
Advanced
Current Issue
First Edition
Future Articles
Archives
Submit to Blood
Search
American Society of Hematology
Meeting Abstracts
Email Alerts
Blood, 1 February 2008, Vol. 111, No. 3, pp. 1404-1412.
Prepublished online as a Blood First Edition Paper on November 6, 2007; DOI 10.1182/blood-2007-09-113761.


This Article
Right arrow Full Text (PDF)
Right arrow Supplemental Figure
Right arrow All Versions of this Article:
blood-2007-09-113761v1
111/3/1404    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Right arrow Rights and Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Nishikawa, H.
Right arrow Articles by Gnjatic, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Nishikawa, H.
Right arrow Articles by Gnjatic, S.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

arrow to previous article Previous Article  |  Next Article next article arrow

Submitted September 19, 2007
Accepted October 28, 2007

Induction of regulatory T cell-resistant helper CD4+ T cells by bacterial vector

Hiroyoshi Nishikawa, Takemasa Tsuji, Elke Jager, Gabriel Briones, Gerd Ritter, Lloyd J Old, Jorge E Galan, Hiroshi Shiku, and Sacha Gnjatic*

Ludwig Institute for Cancer Research, Memorial Sloan-Kettering Cancer Center, New York, NY, United States
Medizinische Klinik II, Hamatologie-Onkologie, Krankenhaus Nordwest, Frankfurt, Germany
Section of Microbial Pathogenesis, Yale University School of Medicine, New Haven, CT, United States
Department of Immuno-Gene Therapy, Mie University Graduate School of Medicine, Tsu, Mie, Japan

* Corresponding author; email: gnjatics{at}mskcc.org.

Salmonella typhimurium engineered to deliver cancer/testis antigen NY-ESO-1 through type III secretion (S. typhimurium-NY-ESO-1) was shown to be an efficient cancer vaccine construct in mice and to stimulate NY-ESO-1-specific CD8+/CD4+ T cells in vitro in cancer patients with NY-ESO-1 spontaneous immunity. We also showed that individuals without spontaneous immunity to NY-ESO-1 had specific CD4+ T cell precursors with high-avidity to NY-ESO-1 under tight control by CD4+CD25+ regulatory T cells (Tregs). We now found that in healthy donors and melanoma patients without NY-ESO-1 spontaneous immunity, S. typhimurium-NY-ESO-1 elicits CD4+ T helper 1 (Th1) cells in vitro recognizing naturally processed antigen from these high-avidity NY-ESO-1-specific naive precursors. In contrast to peptide stimulation, induction of specific Th1 cells with S. typhimurium-NY-ESO-1 did not require in vitro depletion of CD4+CD25+ Tregs and this prevailing effect was partially blocked by disruption of interleukin-6 or glucocorticoid-induced TNF receptor (GITR) signals. Furthermore, S. typhimurium-induced Th1 cells had higher GITR expression than peptide-induced Th1 cells and were resistant to suppression by CD4+CD25+ Tregs in a GITR dependent fashion. We propose that S. typhimurium-NY-ESO-1 induces antigen-specific T cell responses that are resistant to suppression by CD4+CD25+ Tregs.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
Cancer Res.Home page
C. Jandus, G. Bioley, D. Dojcinovic, L. Derre, L. Baitsch, S. Wieckowski, N. Rufer, W. W. Kwok, J.-M. Tiercy, I. F. Luescher, et al.
Tumor Antigen-Specific FOXP3+ CD4 T Cells Identified in Human Metastatic Melanoma: Peptide Vaccination Results in Selective Expansion of Th1-like Counterparts
Cancer Res., October 15, 2009; 69(20): 8085 - 8093.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
T. Tsuji, N. K. Altorki, G. Ritter, L. J. Old, and S. Gnjatic
Characterization of Preexisting MAGE-A3-Specific CD4+ T Cells in Cancer Patients and Healthy Individuals and Their Activation by Protein Vaccination
J. Immunol., October 1, 2009; 183(7): 4800 - 4808.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
S. Gnjatic, N. K. Altorki, D. N. Tang, S.-M. Tu, V. Kundra, G. Ritter, L. J. Old, C. J. Logothetis, and P. Sharma
NY-ESO-1 DNA Vaccine Induces T-Cell Responses That Are Suppressed by Regulatory T Cells
Clin. Cancer Res., March 15, 2009; 15(6): 2130 - 2139.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
H. Nishikawa, T. Kato, M. Hirayama, Y. Orito, E. Sato, N. Harada, S. Gnjatic, L. J. Old, and H. Shiku
Regulatory T Cell-Resistant CD8+ T Cells Induced by Glucocorticoid-Induced Tumor Necrosis Factor Receptor Signaling
Cancer Res., July 15, 2008; 68(14): 5948 - 5954.
[Abstract] [Full Text] [PDF]



 click for free articles
home about blood authors subscriptions permissions advertising public access contact us
  Copyright © 2007 by American Society of Hematology         Online ISSN: 1528-0020